On Dec. 13, Celltrion Group announced a cash dividend of 500 won (US$0.38) per share for Celltrion common stock, totaling 103.7 billion won.
Celltrion Healthcare will receive dividends as a shareholder in the consolidated Celltrion through a new share integration, with the record date set for Dec. 31.
The cash dividend amount has increased by over 40 percent, rising from 71.8 billion won last year to over 1 trillion won this year. The company has stated its intention to strengthen shareholder returns in the future, revealing plans to further increase cash dividends to around 30 percent of profits.
Furthermore, Celltrion plans to conduct a share buyback of approximately 423.6 billion won in January of next year, involving the retirement of 2.31 million treasury shares, in order to minimize stock dilution. The company explained that the anticipated actual dividend effect resulting from the reduction in the number of total issued shares is estimated to be around 1.0 percent.
Considering growth prospects and cash flow, Celltrion Pharm will distribute 0.05 shares of common stock per share. The total number of shares to be issued for stock dividends is 1,972,158 shares worth approximately 168.8 billion won. The approval for dividends and dividend shares from both companies is expected to be finalized at the regular shareholders’ meeting next year, with disbursement scheduled within one month thereafter.